Matzim LA
- Generic Name: dltiazem hydrochloride extended release tablets
- Brand Name: Matzim LA
Matzim LA (Dltiazem Hydrochloride Extended Release Tablets) side effects drug center
-
Related Drugs
Afeditab CR Avapro Benicar Benicar HCT Bumex Caduet Cardura Cardura XL Carospir Cartia Catapres Catapres-TTS Cozaar Demadex Diovan Diovan HCT Exforge Exforge HCT Hyzaar Inderal Inderal LA Inderal XL Kapspargo Sprinkle Katerzia Lasix Lotensin Lotensin Hct Micardis Micardis HCT Norvasc Prinivil Procardia Procardia XL Qbrelis Tenormin IV Injection Zestril
Matzim LA Side Effects Center
What Is Matzim LA?
Matzim LA (diltiazem hydrochloride) are a nondihydropyridine calcium channel blocker used to treat high blood pressure (hypertension), to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and heart attacks. It can be used alone or in combination with other antihypertensives. Matzim LA is also used for improving exercise tolerance in patients with chronic stable angina.
What Are Side Effects of Matzim LA?
Side effects of Matzim LA include:
- lower limb fluid retention (edema),
- sinus congestion,
- rash,
- headache,
- dizziness,
- fatigue,
- slow heart rate,
- first degree AV block, and
- cough
Dosage for Matzim LA
The initial adult dose of Matzim LA to treat hypertension is 180 to 240 mg once daily. Adjust dose according to blood pressure response to a maximum of 540 mg daily. The initial adult dose of Matzim LA to treat angina is 180 mg once daily. Adjust dose according to response to a maximum of 360 mg.
Matzim LA In Children
Safety and effectiveness of Matzim LA in pediatric patients have not been established.
What Drugs, Substances, or Supplements Interact with Matzim LA?
Matzim LA may interact with other medicines such as:
- beta blockers,
- digitalis,
- other agents known to impair cardiac contractility,
- ivabradine, and
- CYP450 3A4 substrates such as simvastatin and rifampin
Tell your doctor all medications and supplements you use.
Matzim LA During Pregnancy and Breastfeeding
Tell your doctor if you are pregnant or plan to become pregnant before using Matzim LA; it may harm a fetus. Matzim LA passes into breast milk. Because of the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended while using Matzim LA.
Additional Information
Our Matzim LA (diltiazem hydrochloride) Extended Release Tablets, for Oral Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Matzim LA Consumer Information
Get emergency medical help if you have signs of an allergic reaction (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling).
Call your doctor at once if you have:
- chest pain;
- slow heartbeats;
- pounding heartbeats or fluttering in your chest;
- a light-headed feeling, like you might pass out; or
- heart problems--swelling, rapid weight gain, feeling short of breath.
Common side effects may include:
- swelling;
- dizziness, weakness;
- headache;
- nausea; or
- rash.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Matzim LA (Dltiazem Hydrochloride Extended Release Tablets)
Matzim LA Professional Information
SIDE EFFECTS
The following adverse reactions are described in greater detail, in other sections:
- Bradycardia and AV block [see WARNINGS AND PRECAUTIONS]
- Heart failure [see WARNINGS AND PRECAUTIONS]
- Acute hepatic injury [see WARNINGS AND PRECAUTIONS]
- Severe skin reactions [see WARNINGS AND PRECAUTIONS]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
For the hypertension studies, the following table presents adverse reactions more common on diltiazem than on placebo (but excluding events with no plausible relationship to treatment), as reported in placebo-controlled hypertension trials in patients receiving a diltiazem hydrochloride extended-release formulation (once-a-day dosing) up to 540 mg.
| Adverse Reactions (MedDRA Term) | Placebo | Diltiazem hydrochloride extended-release | |
| n=120 # pts. (%) | 120-360 mg n=501 # pts. (%) | 540 mg n=123 # pts. (%) | |
| Edema lower limb | 4 (3) | 24 (5) | 10 (8) |
| Sinus congestion | 0 (0) | 2 (1) | 2 (2) |
| Rash | 0 (0) | 3 (1) | 2 (2) |
In the angina study, the adverse event profile of Matzim LA (diltiazem hydrochloride) extended-release tablets was consistent with what has been previously described for Matzim LA (diltiazem hydrochloride) extended-release tablets and other formulations of diltiazem HCl. The most frequent adverse effects experienced by Matzim LA (diltiazem hydrochloride) extended-release tablets-treated patients were edema lower-limb (6.8%), dizziness (6.4%), fatigue (4.8%), bradycardia (3.6%), first-degree atrioventricular block (3.2%), and cough (2%).
In addition, the following events have been reported infrequently (less than 1%) in angina or hypertension trials:
Cardiovascular: Angina, bundle branch block, palpitations, syncope, tachycardia, ventricular extrasystoles [see WARNINGS AND PRECAUTIONS].
Nervous System: Abnormal dreams, amnesia, depression, gait abnormality, hallucinations, insomnia, nervousness, paresthesia, personality change, somnolence, tinnitus, tremor.
Gastrointestinal: Anorexia, constipation, diarrhea, dry mouth, dysgeusia, dyspepsia, thirst, vomiting, weight increase.
Dermatological: Petechiae, photosensitivity, pruritus, urticaria [see WARNINGS AND PRECAUTIONS].
Other: Amblyopia, CPK increase, dyspnea, epistaxis, eye irritation, hyperglycemia, hyperuricemia, impotence, muscle cramps, nasal congestion, nocturia, osteoarticular pain, polyuria, sexual difficulties.
Post-Marketing Experience
The following adverse reactions have been identified during post-approval use of diltiazem. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or establish a causal relationship to drug exposure.
The following post-marketing reactions have been reported infrequently in patients receiving diltiazem: acute generalized exanthematous pustulosis, allergic reactions, alopecia, angioedema (including facial or periorbital edema), erythema multiforme, extrapyramidal symptoms, gingival hyperplasia, hemolytic anemia, increased bleeding time, leukopenia, photosensitivity (including lichenoid keratosis and hyperpigmentation at sunexposed skin areas), purpura, retinopathy, myopathy, and thrombocytopenia.
In addition, events such as myocardial infarction have been observed which are not readily distinguishable from the natural history of the disease in these patients.
A number of well-documented cases of generalized rash, some characterized as leukocytoclastic vasculitis, have been reported.
Read the entire FDA prescribing information for Matzim LA (Dltiazem Hydrochloride Extended Release Tablets)
&Copy; Matzim LA Patient Information is supplied by Cerner Multum, Inc. and Matzim LA Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.